Skip to content
Screener

ImmunityBio, Inc. IBRX Fair value option changes in fair value

Fair value option changes in fair value at other companies

LanzaTech Global, Inc. logo
LanzaTech Global, Inc.LNZA
-$100K+99.1%
Intercontinental Exchange logo
Intercontinental ExchangeICE
$0—
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$236.63M-456%
Finance of America Companies logo
Finance of America CompaniesFOA
-$3.45M—
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$6.76M-27.9%
DeFi Development Corp. logo
DeFi Development Corp.DFDV
$0—

Segments

By segment

See full
Reportable Segment-$236.63M-456%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.68B+242%
Enterprise value$7.92B+227%
P/S54.5×+14.8×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%—
Debt / equity0.1×—
Current ratio6.7×+4.4×